A

Arecor Therapeutics PLC
LSE:AREC

Watchlist Manager
Arecor Therapeutics PLC
LSE:AREC
Watchlist
Price: 80 GBX 1.27%
Market Cap: 30.2m GBX

Net Margin
Arecor Therapeutics PLC

-160.1%
Current
-275%
Average
-6.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-160.1%
=
Net Income
-8.1m
/
Revenue
5.1m

Net Margin Across Competitors

No Stocks Found

Arecor Therapeutics PLC
Glance View

Market Cap
30.2m GBX
Industry
Biotechnology

Arecor Therapeutics Plc is a biopharmaceutical company that targets improving patient care by bringing medicines to market through the enhancement of existing therapeutic products. The firm targets improving patient care by bringing medicines to market through the existing therapeutic products. The company partners with global pharmaceutical and biotechnology companies to apply the Arestat technology to their products under a technology licensing model. These products can be at any stage in development from early phase clinical development through to products that are already on the market. The areas of applications of the technology are biologicals, biosimilars, therapeutic vaccines and therapeutic peptides.

AREC Intrinsic Value
20.08 GBX
Overvaluation 75%
Intrinsic Value
Price
A
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-160.1%
=
Net Income
-8.1m
/
Revenue
5.1m
What is the Net Margin of Arecor Therapeutics PLC?

Based on Arecor Therapeutics PLC's most recent financial statements, the company has Net Margin of -160.1%.

Back to Top